946 related articles for article (PubMed ID: 17085667)
1. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
[TBL] [Abstract][Full Text] [Related]
2. Dual promoter-controlled oncolytic adenovirus CG5757 has strong tumor selectivity and significant antitumor efficacy in preclinical models.
Li Y; Idamakanti N; Arroyo T; Thorne S; Reid T; Nichols S; VanRoey M; Colbern G; Nguyen N; Tam O; Working P; Yu DC
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8845-55. PubMed ID: 16361574
[TBL] [Abstract][Full Text] [Related]
3. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
4. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
[TBL] [Abstract][Full Text] [Related]
5. Transthyretin-driven oncolytic adenovirus suppresses tumor growth in orthotopic and ascites models of hepatocellular carcinoma.
Hsieh JL; Lee CH; Teo ML; Lin YJ; Huang YS; Wu CL; Shiau AL
Cancer Sci; 2009 Mar; 100(3):537-45. PubMed ID: 19134007
[TBL] [Abstract][Full Text] [Related]
6. Gene-viral cancer therapy using dual-regulated oncolytic adenovirus with antiangiogenesis gene for increased efficacy.
Su C; Na M; Chen J; Wang X; Liu Y; Wang W; Zhang Q; Li L; Long J; Liu X; Wu M; Fan X; Qian Q
Mol Cancer Res; 2008 Apr; 6(4):568-75. PubMed ID: 18344493
[TBL] [Abstract][Full Text] [Related]
7. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity.
Irving J; Wang Z; Powell S; O'Sullivan C; Mok M; Murphy B; Cardoza L; Lebkowski JS; Majumdar AS
Cancer Gene Ther; 2004 Mar; 11(3):174-85. PubMed ID: 14726958
[TBL] [Abstract][Full Text] [Related]
8. [hTERT promoter regulated replication-selective adenovirus CNHK300 in treatment of hepatocellular carcinoma].
Li YM; Song ST; Jiang ZF; Zhang Q; Su CQ; Xu JM; Qian YZ; Qian QJ
Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(7):468-72. PubMed ID: 15854553
[TBL] [Abstract][Full Text] [Related]
9. Oncolytic effects of adenovirus mutant capable of replicating in hypoxic and normoxic regions of solid tumor.
Cho WK; Seong YR; Lee YH; Kim MJ; Hwang KS; Yoo J; Choi S; Jung CR; Im DS
Mol Ther; 2004 Nov; 10(5):938-49. PubMed ID: 15509511
[TBL] [Abstract][Full Text] [Related]
10. A novel A33 promoter-based conditionally replicative adenovirus suppresses tumor growth and eradicates hepatic metastases in human colon cancer models.
Cafferata EG; Macció DR; Lopez MV; Viale DL; Carbone C; Mazzolini G; Podhajcer OL
Clin Cancer Res; 2009 May; 15(9):3037-49. PubMed ID: 19336523
[TBL] [Abstract][Full Text] [Related]
11. Functional interactions of antiapoptotic proteins and tumor necrosis factor in the context of a replication-competent adenovirus.
Liu TC; Wang Y; Hallden G; Brooks G; Francis J; Lemoine NR; Kirn D
Gene Ther; 2005 Sep; 12(17):1333-46. PubMed ID: 15920462
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of hepatocellular carcinoma with a novel gene-viral therapeutic system CNHK300-murine endostatin].
Li GC; Nie MM; Yang JM; Su CQ; Sun LC; Qian YZ; Sham J; Fang GE; Wu MC; Qian QJ
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):943-8. PubMed ID: 15329284
[TBL] [Abstract][Full Text] [Related]
13. Telomerase-dependent oncolytic adenovirus for cancer treatment.
Huang TG; Savontaus MJ; Shinozaki K; Sauter BV; Woo SL
Gene Ther; 2003 Aug; 10(15):1241-7. PubMed ID: 12858189
[TBL] [Abstract][Full Text] [Related]
14. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
15. A simplified system for generating oncolytic adenovirus vector carrying one or two transgenes.
Hu ZB; Wu CT; Wang H; Zhang QW; Wang L; Wang RL; Lu ZZ; Wang LS
Cancer Gene Ther; 2008 Mar; 15(3):173-82. PubMed ID: 18157145
[TBL] [Abstract][Full Text] [Related]
16. A novel triple-regulated oncolytic adenovirus carrying PDCD5 gene exerts potent antitumor efficacy on common human leukemic cell lines.
Xie M; Niu JH; Chang Y; Qian QJ; Wu HP; Li LF; Zhang Y; Li JL; Huang XJ; Ruan GR
Apoptosis; 2009 Sep; 14(9):1086-94. PubMed ID: 19551515
[TBL] [Abstract][Full Text] [Related]
17. Complete eradication of hepatomas using an oncolytic adenovirus containing AFP promoter controlling E1A and an E1B deletion to drive IL-24 expression.
Zhang KJ; Zhang J; Wu YM; Qian J; Liu XJ; Yan LC; Zhou XM; Xiao RJ; Wang YG; Cao X; Wei N; Liu XR; Tang B; Jiao XY; Chen K; Liu XY
Cancer Gene Ther; 2012 Sep; 19(9):619-29. PubMed ID: 22790965
[TBL] [Abstract][Full Text] [Related]
18. Potent antitumoral effects of a novel gene-viral therapeutic system CNHK300-mEndostatin in hepatocellular carcinoma.
Li GC; Yang JM; Nie MM; Su CG; Sun LC; Qian YZ; Fang GE; Sham J; Wu MC; Qian QJ
Chin Med J (Engl); 2005 Feb; 118(3):179-85. PubMed ID: 15740644
[TBL] [Abstract][Full Text] [Related]
19. Oncolytic adenovirus that overproduces ADP and replicates selectively in tumors due to hTERT promoter-regulated E4 gene expression.
Kuppuswamy M; Spencer JF; Doronin K; Tollefson AE; Wold WS; Toth K
Gene Ther; 2005 Nov; 12(22):1608-17. PubMed ID: 16034456
[TBL] [Abstract][Full Text] [Related]
20. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
